Bariatric surgery linked to fewer kidney failures and deaths

What happened

Research presented May 5, 2026 at the American Society for Metabolic and Bariatric Surgery annual meeting in San Antonio tracked more than 8,900 adults with obesity and chronic kidney disease through five years of follow-up and found substantially fewer kidney failures, cardiovascular events, and deaths among those who had surgery. A Cleveland Clinic team used the TriNetX Research Network electronic health record database covering 2010 through 2020, matched 4,481 patients who had sleeve gastrectomy or Roux-en-Y gastric bypass one-to-one to 4,481 similar patients who did not have surgery, with matching on demographics, comorbidities, baseline kidney function, and medication use.

At five years, end-stage kidney disease had developed in 5.9 percent of the surgery group versus 11.9 percent of the non-surgery group. Dialysis dependence was 4.1 percent versus 9 percent. Composite cardiovascular outcomes, heart attack and stroke combined, were 15.5 percent versus 27.7 percent. All-cause mortality was 5 percent versus 16 percent, a drop the society's release characterized as over 75 percent lower. One number ran the other direction: kidney transplantation was more than twice as common after surgery, 4.6 percent versus 2.2 percent, which the authors frame as greater access to life-saving transplants rather than a harm.

Lead author Jerry Dang, associate professor of surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, said the findings show metabolic and bariatric surgery does not just treat obesity but fundamentally alters the course of chronic kidney disease and should be considered earlier in the disease process, before organ failure. ASMBS president Richard Peterson, who was not involved in the study, called the survival benefit extraordinary but consistent with how these operations change chronic-disease trajectories.

What it means

For someone with obesity and chronic kidney disease already weighing surgery, this is meeting-level evidence that in matched real-world records the operated group experienced roughly half the kidney failure, half the cardiovascular events, and about a third of the deaths over five years. It is a reason to raise timing with both a surgical team and a kidney team, since the lead author's central argument is that surgery considered earlier in CKD, before dialysis or transplant becomes the conversation, is where the benefit showed up.

The transplant figure deserves its own reading. More transplants after surgery is good news only in context: surgery patients lived long enough and were well enough to be listed and receive kidneys. It is not an independent claim that surgery gets you a transplant.

What it does not mean

This is not a randomized trial and it does not prove that every patient with obesity and chronic kidney disease should be operated on, or that medication has no role in this population. Matching in an electronic-record database balances observed characteristics such as comorbidities, baseline kidney function, and medication use, but it cannot remove selection effects between people who reach surgery and people who do not; coded claims data can also misclassify events. The work was presented as abstract 4520 by Kachornvitaya and colleagues and is meeting evidence, not a finished peer-reviewed paper. The society publishing the release advocates for the procedure. It is not individualized advice.